title: [Clinical management and prognostic analysis of primary peritoneal neoplasms].
abstract: OBJECTIVE
  To investigate the clinical management strategies and prognostic factors of primary peritoneal neoplasms.
  
  
  METHODS
  We retrospectively reviewed the clinical and pathological records of 24 cases with primary peritoneal neoplasms treated in the People's Hospital, Peking University during May 1995 and April 2004.
  
  
  RESULTS
  Among 24 cases, 15 patients were diagnosed as serous papillary adenocarcinoma (9 highly and intermediately differentiated, and 6 lowly differentiated), 6 as mixed epithelial carcinoma and 3 as mixed malignant Mullerian tumor (MMMT). All patients underwent cytoreductive surgery, 21 cases having, suboptimal debulking one. Then they received a platinum-based chemotherapy. Thirteen cases received paclitaxel + cisplatin (TP) and 9 received cisplatin + doxorubicin + cyclophosphamide (PAC) combination chemotherapy. The primary response reached 80% (complete response 55% and partial response 25%). The median survival of all patients was 42 months (95% CI = 22-62 months). Survival for patients with primary peritoneal serous papillary carcinoma (PPSPC), mixed epithelial carcinoma and MMMT was 44, 19 and 13 months respectively, with a significant difference between PPSPC and MMMT (P < 0.05). Patients receiving TP combination also exhibited longer survival than those receiving PAC regimen (mean survival 75 vs 28 months, P < 0.05).
  
  
  CONCLUSIONS
  Patients with primary peritoneal neoplasms should be treated with appropriate cytoreductive surgery. A primary surgical protocol is bilateral salpingo-oophorectomy and omentectomy. Overestimating an optimal debulking surgery may have no benefit on the survival. TP combination therapy may bring longer survival than PAC regimen. Histopathologic types and chemotherapy regimens are the essential factors of the prognosis.
authors.affiliation: Department of Gynecological Malignancy Center, People's Hospital, Peking University, Beijing 100044, China.
authors.forename: Chao
authors.initials: C
authors.lastname: Zhang
authors.forename: Heng
authors.initials: H
authors.lastname: Cui
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhao
authors.forename: Xu-dong
authors.initials: XD
authors.lastname: Liang
authors.forename: Chao-hua
authors.initials: CH
authors.lastname: Wang
authors.forename: Xiao-ping
authors.initials: XP
authors.lastname: Li
authors.forename: Dan-hua
authors.initials: DH
authors.lastname: Shen
authors.forename: Shi-jun
authors.initials: SJ
authors.lastname: Wang
authors.forename: Li-hui
authors.initials: LH
authors.lastname: Wei
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome